Periodic Reporting for period 2 - ONCOSMART (ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics)
Reporting period: 2019-09-01 to 2020-08-31
Every year about 20 million people are diagnosed with cancer and about 10 million cancer patients see their disease advancing and becoming hard to treat, e.g. refractory to treatments and/or developing metastases. At the same time 95% oncology trials fail mainly because of a lack of efficacy of the new treatment. There is an urgent need to better match patients and drugs. Precision medicine based on genomic profiling can be applied only to a minority of advanced cancer patients (about 15%) and eventually provide a benefit to some 7% of “hard-to-treat” cancer patients.
The “functional profiling” approach pursued by ONCOSMART is applicable to any cancer patient, independently from the genetic makeup. Moreover, in lab-based tests it has shown superior performance – compared to molecular/genomic profiling – in predicting individual patient’s response to treatments.
ONCOSMART key objective is to develop the first fully automated and standardised platform allowing to advance functional precision medicine from a lab-based to a device-based approach. ONCOSMART system enables de-centralized execution of functional profiling tests and aims at supporting a wide adoption in research and clinical labs, with the goals to identify the most suitable cancer therapy for individual patients and support drug repurposing and patient selection in clinical trials.
ONCOSMART can test anticancer drugs including targeted, chemo and immunotherapies alone or in combination.
The platform is being developed and tested on leukemia patients (AML), proving its predictive power, and is meant to be extended to other hematologic and solid tumors in future developments.
Within this project, CellPly has the goal to industrialise the platform, validate its analytical and clinical performance and support the first commercialisation activities releasing the platform for research first, then for clinical use.
- BETA system characterized, ready for commercialization
- Mark I platform mechanical design completed, assembly ongoing
- Developed ready-to-use consumable kits with microfluidic device and reagents for characterizing drug response in AML, CLL and MM developed
- Signed agreement with multinational contract manufacturer for Mark I industrialization
- Research-grade analytical SW released, in use for day-by-day analysis of data acquired from real patients’ samples
- Extended use of platform to functional analysis of immune cells at scale, suitable for cell therapy and immunotherapy characterization with single-cell resolution
- Developed single-cell ADCC method to characterize monoclonal antibodies efficacy
Preclinical and clinical validation
- Quality management procedures issued to manage core processes, e.g. platform industrialization and clinical validation activities according to ISO13485 requirements
- Demonstrated independent use of BETA instrument from remote partner (Charité hospital, Berlin);
- Pilot study carried out at 2 main hospitals (Sant’Orsola Malpighi Hospital, Italy and Charité hospital, Germany)
- 4 hospitals currently involved in sample collection (Ravenna hospital, IRST oncology institute in Forlì-Cesena)
- Validation of BETA system completed on about 52 patients, reporting a high prediction accuracy
- Method developed and proof of concept completed reporting possible use of frozen samples for predicting clinical outcome of AML patients
Marketing, comm/diss. activities
• Started sale of consumables to partner clinics
• Ready for selling BETA system to selected customers / partners
• Currently offering therapy testing services to selected customers / partners
• 3 Key Opinon Leaders (KOL), i.e. medical doctors with top-level publication rates, involved in our clinical studies (one KOL for each study)
• 1 abstract presented at ASH 2019 (largest international hematology congress)
• Company and project presented at 14 international events (business, partnering, pitch events)
• Early-engagement agreement signed with Roche, as a follow-up of interactions started within the EIC’s Business Acceleration Services program
For biopharmaceutical companies, blood cancers are a relevant field as, among 600 drugs under phase 2-3 development in oncology, 200 are being developed in blood cancers. ONCOSMART can support drug development by:
a) previewing the efficacy of drugs in patient sets and for indications never tested before
b) stratifying patients and tailoring recruitment of patients in different phases of clinical trials
c) supporting Companion Diagnostic (CDx) programs
In clinical settings, mutational/genetic are mainly used as prognostic markers and have poor predictive value. ONCOSMART has the opportunity to introduce predictive biomarkers with high predictive value.
Functional profiling approaches are being developed by a growing number of companies and research groups. CellPly, thanks to the current development and the latest IP developed within the project, is aligned to the most advanced methods developed by state-of-the-art companies in the field, allowing to precisely evaluate the efficacy of drugs on the tumor subpopulation separated from healthy cells and to analyze the immune system activity for immunotherapy profiling. Beyond this, ONCOSMART advances existing solutions by providing, for the first time, an integrated system enabling decentralized analysis of ex-vivo tumor response to treatments. This is as fundamental step towards the adoption of functional precision medicine in diagnostic procedures, including CDx.
ONCOSMART is being validated in clinical settings where high-cost treatments, e.g. targeted therapies, combination regimens and immunotherapies, are in use. Therapy cost has reached, in many cases, the range of €0.1-1 million per patient, posing a serious concern about economic sustainability and general access to latest-generation treatments. Healthcare expenditure in the EU is about €60 billion for cancer treatment, €6-8 billion only for blood cancers. ONCOSMART can deeply impact on these costs and support value-based healthcare models providing payers with data-driven reimbursement strategies.
Recently, OSNOSMART use has been demonstrated on a broader spectrum of therapies, including drug-based immunotherapies (e.g. monoclonal antibodies) and cell therapies. Cancer immunotherapies represent the fastest growing segment of the pharmaceutical industry with a 25% market share in terms of number of agents in preclinical or clinical pipeline. ONCOSMART provides the opportunity also to accelerate the discovery and development of these therapies with a market opportunity in the €3billion range, growing to €9 billion by 2025, only for tests supporting the R&D of new therapeutic products in immuno-oncology.